The IMPACCT Rapid Program prospectively evaluates medicines that are used on a day-to-day basis so that clinicians can make better decisions at the bedside.
Rapid Adult Program
Adult
Anti-depressants for depression in palliative care - series 49
Help us guide clinicians in their understanding of which antidepressant agent could be best suited for different palliative patient profiles.
The assessment and management of depression can be challenging due to the symptoms and complications of advanced illnesses. To date, it is unclear if patients tolerate and receive actual benefit from antidepressants in real-world palliative care clinical practice, particularly when life expectancy is in the range of days to weeks.
The series will compare the clinical benefits and harms of four commonly prescribed antidepressant agents in palliative care: mirtazapine, duloxetine, citalopram and escitalopram.
By collecting data for this series, you will be helping us to understand clinicians’ prescribing practices, as well as the harms and benefits of antidepressant use in the palliative care setting.
learn more - read the series manual (pdf, 178kb)
collect data - download the case report form (pdf, 620kb)
Benzodiazepines for breathlessness - series 10
Benzodiazepines are sedative medications that are recommended for short-term use in the treatment of anxiety and insomnia. For some time now, benzodiazepines are also routinely recommended and prescribed as adjuvant agents in the palliation of breathlessness. However, there is no evidence for or against benzodiazepines for the relief of breathlessness in people with advanced cancer and COPD. A systematic review highlighted that benzodiazepines cause more drowsiness as an adverse effect compared to placebo and suggested that benzodiazepines may be considered as a second- or third-line treatment when opioids and non-pharmacological measures have failed to control breathlessness.
This phase IV pharmacovigilance study is uniquely examining real clinical experience when palliative care patients receive benzodiazepines as part of their dyspnoea management. This is very important data as it will not only enhance understanding of the reasons that clinicians choose to prescribe benzodiazepines but also examine the safety of the process.
learn more - read the series manual (pdf, 149kb)
collect data - download the case report form (pdf, 303kb)
Compression and related physical therapies for lymphoedema - series 25
Are you treating cancer-related limb lymphoedema with compression or related physical therapies?
Lymphoedema is a common problem in cancer patients where lymphatic flow is obstructed by the cancer itself or by a complication of the cancer. Compressive bandaging, manual lymphatic drainage and other related therapies are often used by physiotherapists, occupational therapists and other clinicians to reduce or control lymphoedema. However, there is limited evidence supporting their use for cancer-related lymphoedema, particularly in palliative care, where patients may find such therapies painful or burdensome.
Help us explore the use, efficacy, side effect and complication profile of compression and related therapies in the management of cancer-related limb lymphoedema in palliative care.
learn more - read the series manual (pdf, 178kb)
Collect data - download the case Report Form (pdf, 413kb)
Diuretics for cancer-related lymphoedema - series 26
Are you treating cancer-related lymphoedema with diuretics?
You can help us explore the use, efficacy, side effects and complications of diuretics in the management of cancer-related limb lymphoedema in palliative care.
There is a lack of evidence supporting the use of diuretics for cancer-related lymphedema, particularly at the end of life. Your data can help improve the evidence about the use of diuretics in palliative care.
learn more - read the series manual (PDF, 142KB)
collect data - download the case report form (pdf, 403kb)
Intrathecal catheters for pain management - series 36
Pain is a common and distressing symptom in the palliative care patient population. Even with multimodal, multidisciplinary and patient-centred holistic care, there remains a group of patients in whom pain remains poorly managed, or for whom side effects of systemic medications significantly negatively impact quality of life.
Intrathecal drug delivery is an interventional pain management option that can be considered in this group. Smaller doses (compared with the oral or parenteral routes) of medication/s are delivered into the intrathecal space thereby aiming to maximise efficacy and minimise medication-related side effects such as constipation, nausea, vomiting and drowsiness.
There are several medications available for infusion into the intrathecal space including opioids, local anaesthetics, clonidine and baclofen.
Decision making around intrathecal catheter insertion and the associated medication and infusion system selection takes into consideration several factors including pain location and type, diagnosis and prognosis, patient preference and the availability of local resources and expertise.
The aim of this series is to explore the use, efficacy, complications and side-effect profile of intrathecal drug delivery in the management of patients with life-limiting illnesses.
RAPID SERIES MANUAL - INTRATHECAL CATHETERS FOR PAIN MANAGEMENT SERIES 36 (pdf, 567KB)
CASE REPORT FORM - INTRATHECAL CATHETERS FOR PAIN MANAGEMENT SERIES 36 (PDF, 1648KB)
Medicinal cannabis in palliative care- series 19
There is wide public interest in the role of medicinal cannabis in cancer care generally, and palliative care in particular. Despite this substantial interest, many clinicians in palliative care remain wary of prescribing medicinal cannabis. They cite concerns about the lack of evidence underpinning the role of medical cannabis, concerns about the potential for adverse effects and the unconventional way by which cannabis came to be listed as a medicine in many jurisdictions, including Australia.
This series will address some of these concerns by establishing a significant database of real-time monitoring of patients prescribed cannabis who are receiving palliative care. These data will capture the benefits or effects, as well as adverse effects seen for patients. Specifically, all patients attending palliative care services who are prescribed medical cannabis for any indication will have a series of outcomes documented (1) at time of prescription, and (2) at subsequent standardised follow-up times. Outcomes of interest include evidence of effects upon symptoms such as pain, appetite, nausea, sleep and on overall quality of life. In addition, data will be collected around any evidence of adverse effects such as sedation, confusion and other potential side effects. The doses of cannabis and of other medications prescribed for symptom relief will be collected.
This important study will enable prospective monitoring of a medication that is already available and where the evidence underpinning its use is limited. Australian palliative care services are uniquely placed to contribute to this real-time data monitoring and reporting project with potential to inform practice worldwide.
learn more - read the series manual (pdf, 449kb)
Collect data - download the case Report Form (pdf, 530kb)
Melatonin for insomnia - series 39
Are you prescribing or administering melatonin to people in palliative care?
This series examines the use, efficacy and safety of prescription melatonin for the treatment of insomnia in people receiving palliative care.
Melatonin, secreted by the pineal gland, is a naturally occurring hormone that regulates circadian rhythm and the sleep-wake cycle in humans. Prescription melatonin is regarded as safe and is known to improve quality of sleep as well as morning alertness in people over the age of 55.
Help us collect data to improve the evidence that information best-practice clinical decision making about prescription melatonin in palliative care.
learn more - read the series manual (pdf, 138kb)
collect data - download the case report form (pdf, 342kb)
Mesothelioma-night sweats - series 44
Worried about your patients having night sweats? If you are administering NSAIDS, corticosteroids or paracetamol for night sweats, you can help improve our understanding of how to best manage this troubling symptom.
Night sweats are prevalent for people with advanced malignant mesothelioma and other cancers. They can cause significant sleep disturbance, excessive sleepiness and mood disturbances. This impacts cancer cachexia syndrome leading to a net decrease in the overall quality of life.
Few pharmacological therapies have been trialled in the management of night sweats in people with advanced cancer, including mesothelioma. Due to the lack of evidence, there are no specific pharmacological guidelines to inform how clinicians can best manage night sweats.
This series studies three classes of medications that are often prescribed to treat night sweats – NSAIDS Corticosteroids and paracetamol. There are therefore three separate case report forms for this series – choose the one that matches the medication that you are prescribing or administering.
learn more - read the series manual (PDF, 10KB)
collect data - download the case report FORM for nsaids (pdf, 398kb)
COLLECT DATA - DOWNLOAD THE CASE REPORT FORM FOR CORTICOSTEROIDS (PDF, 448KB)
COLLECT DATA - DOWNLOAD THE CASE REPORT FORM FOR PARACETAMOL (PDF, 398KB)
Ondansetron for nausea and vomiting - series 48
Nausea is a common and distressing symptom for people with advanced illness. While nausea caused by chemotherapy and/or radiotherapy has been intensively studied and multiple medications, including ondansetron, have proven to be beneficial, it has not been effectively studied for people with non-cancer-related nausea. Despite this, it has become common clinical practice to prescribe ondansetron for nausea for non-cancer-related nausea.
In this series, we seek to understand the role of ondansetron for people with nausea unrelated to cancer treatment. The focus is on the patient profile when it is used, the drug's efficacy, and the associated adverse effects.
You can collect data for this series to help us better understand the effects of this medication.
LEARN more - read the series manual (pdf, 389kb)
collect data - download the case report form (pdf, 248kb)
Opioids for symptomatic breathlessness - series 21
Breathlessness can be a frightening and overwhelming problem that is difficult to treat. For many people, breathlessness remains when all the underlying causes of breathlessness have been optimally managed (chronic breathlessness). Breathlessness in these circumstances often occurs at rest or doing routine things like showering or preparing meals.
The prevalence of chronic breathlessness will continue to increase as the population ages because the chronic progressive diseases where breathlessness is common are increasing in prevalence. Nearly one-half of all people experience distressing breathlessness during the last year of life.
We are re-launching this series and the Case Report Form (CRF) now has only three time points, T0, T1 and T2. This should make it easier for sites to participate in this series and significantly reduce the time it takes to complete the CRF.
learn more - read the series manual (pdf, 149kb)
collect data - download the case report form (pdf, 303kb)
PERT for Pancreatic Cancer - series 53
A common complication of pancreatic cancer is pancreatic exocrine insufficiency (PEI), caused by the cancer directly, or functionally through blocked ducts. This lack of enzyme secretion into the duodenum often leads to malabsorption and symptoms such as bloating, wind, nausea, abdominal pain, diarrhoea and anorexia.
The treatment for PEI is pancreatic enzyme replacement treatment (PERT), a biological medication administered in capsule form which aids in digestion. There is evidence that PERT is well tolerated and helps with symptom management, weight stabilisation, the ability to tolerate oncology treatments, and even survival. However, there is also published literature highlighting the low rates of prescribing PERT among clinicians for people with pancreatic cancer around the world.
This study seeks to understand clinicians’ prescribing practices, and explore the use, efficacy and safety of PERT for patients with pancreatic cancer.
learn more - read the series manual (pdf, 214kb)
collect data - download the case report form (pdf, 421kb)
Temazepam for insomnia - series 47
What is the real clinical experience when people in palliative care receive Temazepam for insomnia?
In this series, we will explore the use, efficacy and safety of Temazepam, a benzodiazepine, for the treatment of insomnia in palliative care.
Insomnia impacts physical, psychological and social aspects of life. Improving sleep using safe, effective and accessible pharmacotherapy is a tangible way to improve quality of life for people receiving palliative care.
But, there are challenges with prescribing benzodiazepines, especially when co-prescribed with opioids. You can collect data for this series to help us better understand the clinical experience of Temazepam for insomnia.
learn more - read the series manual (pdf, 134kb)
collect data - download the case report form (pdf, 342kb)
Nursing
Dressings for malignant cutaneous wounds - series 38
Can you help us? If you are looking after wounds that won't heal, we want to hear from you. You can collect data to help us understand common practices for managing malignant cutaneous wounds.
In this series, we want to identify the wound management procedures clinicians use for malignant cutaneous wounds, how clinicians decide on what course of management they will take for the wound, and which management/s achieve the goals of care.
Malodour is an overwhelming concern for the person with the wound, their family, and carers. The physiological, psychological and sociological consequences of living with a malodorous wound have a dramatic impact on comfort, pain, and quality of life.
The holistic management of these wounds is challenging. There is no robust evidence for which of the current treatment options are the most effective at improving quality of life or managing symptoms. Join this series to improve the evidence for best practice.
learn more - read the series Manual (pdf, 140kb)
Collect data - download the case Report Form (pdf, 605kb)
Nursing interventions for constipation - series 33
Are you nursing patients who have constipation? We need your help to collect data about nursing interventions for this important symptom for people in palliative care.
Constipation is a common problem for people in palliative care with laxatives being commonly prescribed. Despite clinical guidelines suggesting medication combinations and daily monitoring, there is little evidence about how nurses assess the need for a constipation intervention and whether the intervention is successful.
Your contribution to this study will help us understand whether nursing assessments and responses to constipation are effective.
learn more - read the series Manual (pdf, 162kb)
Collect data - download the case Report Form (pdf, 266kb)
Nursing interventions for disorientation - series 29
Seeking nurses caring for people who are disoriented. We need your insights to help us understand if current orientation strategies are effective.
Despite clinical guideline recommendations for orientation strategies for disoriented persons, there is a lack of evidence that such strategies are effective or even acceptable to them.
Disorientation is a common problem for people receiving care in hospitals and other facilities. Influencing factors include unfamiliarity of the environment, sensory impairment, prior cognitive impairment, and the impacts of physical illness and medical treatment on a person’s awareness and cognition.
Your data will contribute to our understanding of whether nurses’ use of orientation strategies for disorientated persons in their care are effective and acceptable.
Learn more - read the series manual (PDF, 431KB)
Collect data - download the case Report Form (PDF, 183KB)
